Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00501709 |
Recruitment Status :
Completed
First Posted : July 16, 2007
Last Update Posted : May 6, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Type 1 Diabetes | Drug: Belatacept and Raptiva | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 10 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus |
Actual Study Start Date : | February 2007 |
Actual Primary Completion Date : | December 2016 |
Actual Study Completion Date : | December 2016 |

Arm | Intervention/treatment |
---|---|
Experimental: Treatment
Allogenic pancreatic islet transplant using belatacept and raptiva
|
Drug: Belatacept and Raptiva
immunosuppressant agent to prevent rejection in transplant recipients
Other Name: immunosuppressant |
- lnsulin independence [ Time Frame: monthly ]improved glycemic control

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Type 1 Diabetes
- Metabolic lability/instability characterized by hypoglycemia or ketoacidosis(>2 hospital admissions in the previous year), erratic glucose profiles(MAGE >120mg/dL), or disruption in lifestyle(danger to life, self or others). Reduced awareness of hypoglycemia or > 1 episode in the last 1.5 years of severe hypoglycemia.
- Persistently poor glucose control (as defined by HgbA1c>10% at the end of six months of intensive management efforts with diabetes care team.
-
Progressive secondary complications as defined by
- a new diagnosis by an ophthalmologist of proliferative retinopathy or clinically significant macular edema or therapy with photocoagulation during the last year; or
- urinary albumin excretion rate >300mg/day but proteinuria <3g/day; or
- symptomatic autonomic neuropathy (as defined by postural hypotension in the setting of euvolemia, gastroparesis or diarrhea attributed to diabetic neuropathy, or neuropathic bladder as diagnosed by an urologist)
Exclusion Criteria:
- Patient weighs more than 80kg or body mass index BMI>28
- Patient's insulin requirement is >55 Units/day.
- Current use of immunosuppressive agents.
- History of malignancy within 10 years (except for adequately treated basal or squamous cell CA of the skin).
- Active peptic ulcer disease.
- Severe unremitting diarrhea or other GI disorders potentially interfering with the ability to absorb oral medications.
- Untreated proliferative retinopathy.
- Pregnancy or breastfeeding.
- Female subjects not post-menopausal or surgically sterile, or not using an acceptable method or contraception.
- Active infections.
- Major ongoing psychiatric illness.
- Ongoing substance abuse, drug or alcohol; or recent history of noncompliance.
- Portal hypertension or history of significant liver disease.
- Lymphopenia (<1000/ul) or leukopenia (<3000 total leukocytes/ul) or an absolute CD4 count <500/ul.
- Presence or history of panel-reactive anti-HLA antibody >20%.
- Evidence of acute EBV infection (IgM>IgG) OR no serologic evidence of previous exposure to EBV (IgG>IgM).
- Serologic evidence of infection with HIV or HbsAg or HCV Ab positive.
- Creatinine clearance <60ml/min/m2.
- Positive lymphocytoxic cross-match using donor lymphocytes and serum

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00501709
United States, California | |
University of California, San Francisco | |
San Francisco, California, United States, 94143 |
Principal Investigator: | Peter G Stock, M.D., Ph.D. | University of California, San Francisco | |
Principal Investigator: | Andrew Posselt, M.D., Ph.D. | University of California, San Francisco |
Responsible Party: | University of California, San Francisco |
ClinicalTrials.gov Identifier: | NCT00501709 |
Other Study ID Numbers: |
39-42C |
First Posted: | July 16, 2007 Key Record Dates |
Last Update Posted: | May 6, 2020 |
Last Verified: | April 2020 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Diabetes Mellitus Diabetes Mellitus, Type 1 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Autoimmune Diseases Immune System Diseases Abatacept |
Immunosuppressive Agents Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents |